Avalon GloboCare’s Subsidiary Files Third U.S. Provisional Patent for its Catch-Up Generative AI Video Platform
Rhea-AI Summary
Avalon GloboCare (NASDAQ: ALBT) subsidiary Avalon Quantum AI filed a U.S. provisional patent application (No. 63/961,892) on Feb 18, 2026 for an AI system that generates multiple audience-adaptive commentary video variants from a shared evidence framework while preserving factual integrity.
The platform is designed to tailor tone, pacing, and presentation by audience profile, collect performance data to refine strategies, and adapt outputs for short- and long-form formats, regional/regulatory requirements, and brand-safe distribution. Potential applications cited include personalized financial commentary, sports recaps, and marketing content.
Positive
- Filed U.S. provisional patent No. 63/961,892 on Feb 18, 2026
- Platform aims to generate multiple audience-adaptive video variants
- Design binds all outputs to a shared evidence framework for factual integrity
- Collects performance data to refine future content strategies
Negative
- Application is provisional and not an issued patent
- No commercialization timeline, pricing, or revenue projections disclosed
News Market Reaction
On the day this news was published, ALBT declined 16.07%, reflecting a significant negative market reaction. Argus tracked a peak move of +3.6% during that session. Argus tracked a trough of -25.7% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $715K from the company's valuation, bringing the market cap to $4M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed activity; only LRHC appears in momentum scanners, moving up, while ALBT’s modest -0.22% move suggests stock-specific dynamics.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 22 | AI patent filing | Positive | +1.6% | Subsidiary filed U.S. provisional patent for evidence-constrained AI commentary videos. |
| Jan 20 | KetoAir & AI launch | Positive | -6.0% | FDA registration renewal for KetoAir and planned B2B/B2C launch via Catch-Up platform. |
| Jan 12 | Nasdaq compliance, AI | Positive | -10.2% | Regained Nasdaq equity compliance and began marketing automated generative AI video platform. |
| Dec 30 | AI platform spotlight | Positive | -6.0% | Showcased RPM’s Catch-Up generative AI SaaS and its role in KetoAir marketing. |
| Mar 28 | KetoAir distribution | Positive | +5.8% | Extended exclusivity to distribute KetoAir and AI-enabled software across multiple regions. |
AI-related announcements have produced mixed reactions, with more frequent negative than positive 24h moves despite generally constructive news.
Recent AI-tagged news for Avalon centers on building its generative video and KetoAir ecosystems. Since Dec 30, 2025, the company has highlighted the Catch-Up SaaS platform, regained Nasdaq equity compliance on Jan 12, 2026, renewed FDA registration for KetoAir with a Catch-Up launch planned for Q2 2026, and filed prior AI provisional patents. Price reactions to these AI updates have often been negative, underlining execution and financing concerns despite strategic progress.
Historical Comparison
Across five prior AI-tagged announcements, ALBT’s average 24h move was -2.95%, showing that upbeat AI news has not reliably translated into positive price reactions.
AI-tagged history shows Avalon layering capabilities around its Catch-Up generative video platform and KetoAir distribution, progressing from regional rights and marketing plans to FDA-related updates and multiple AI patent filings supporting evidence-constrained, audience-adaptive video commentary.
Market Pulse Summary
The stock dropped -16.1% in the session following this news. A negative reaction despite another AI patent filing would fit past patterns, where AI-related announcements averaged a -2.95% 24h move. The news extends Avalon’s IP around its Catch-Up platform but does not itself resolve broader concerns tied to prior financings and dilution history. Weakness could reflect ongoing doubts about commercialization timelines and the company’s ability to translate patents into sustainable revenue.
Key Terms
u.s. provisional patent application regulatory
generative ai technical
saas technical
AI-generated analysis. Not financial advice.
Patent Covers Generation of Multiple Audience-Adaptive Commentary Video Variants While Preserving Factual Integrity
FREEHOLD, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that its subsidiary, Avalon Quantum AI LLC, has filed a new U.S. provisional patent application covering an artificial intelligence–driven system designed to generate multiple personalized commentary video variants from a shared evidence framework while preserving factual integrity.
The provisional patent application, titled “Systems and Methods for Audience-Adaptive Generation of Evidence-Preserving Commentary Video Variants” (U.S. Provisional Patent Application No. 63/961,892), addresses a limitation in automated content systems, which traditionally distribute uniform commentary across diverse audiences or optimize for engagement at the expense of factual consistency. This technology is intended to generate multiple versions of the same commentary from a single verified evidence framework, allowing content to be tailored to different audience segments without altering the underlying facts.
The system is designed to analyze audience engagement data, topic preferences, and viewer characteristics to develop audience profiles. From a shared evidence structure, the platform aims to generate customized video variants that may differ in structure, emphasis, tone, pacing, and presentation style, while remaining bound by predefined evidence rules with the goal of ensuring factual consistency across all outputs.
Performance data from each distributed version is continuously collected and used to refine future content strategies. The platform is intended to also adapt content for short-form and long-form formats and align with regional, regulatory, and brand-specific requirements.
Potential applications include personalized financial commentary, sports highlight recaps, and brand-safe marketing content optimized for individual audience segments and distribution channels.
“This patent filing represents an important step in advancing responsible AI-driven personalization,” said Meng Li, Avalon’s Interim Chief Executive Officer and Chief Operating Officer. “Our approach aims to enable increased engagement and monetization while preserving factual integrity across every version of content. By anchoring all outputs to a shared evidence framework, we intend to scale personalization without sacrificing accuracy. We see meaningful commercial potential in applications such as personalized financial commentary tailored to different investor profiles, sports highlight recaps optimized by platform, and brand-safe marketing content customized for specific audiences.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a diversified company focused on the development of precision diagnostic consumer products, the advancement of intellectual property in cellular therapy, and generative artificial intelligence publishing and software. Avalon is currently marketing the KetoAir™ breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAirTM is registered with the U.S. Food and Drug Administration as a Class I medical device. The Company also continues to focus on advancing its intellectual property portfolio through existing patent applications. In addition, Avalon owns and operates commercial real estate.
For more information about Avalon, please visit www.avalon-globocare.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of its products and the product’s ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the SEC, accessible through the SEC’s website (http://www.sec.gov), including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What did Avalon GloboCare (ALBT) file on Feb 18, 2026 regarding AI video technology?
How does Avalon’s AI platform claim to preserve factual integrity across ALBT-generated video variants?
What investor-focused applications did Avalon GloboCare (ALBT) highlight for the new patent filing?
Does the ALBT provisional patent filing guarantee a commercial product or revenue timeline?
What capabilities does Avalon say the patented system will use to tailor video variants for ALBT audiences?
